NEURIZON THERAPEUTICS LIMITED (NUZ)
Share Price Analysis and Chart

07/10/2025

1

Speculative Buy

$0.39

151.61%

The US FDA has accepted Neurizon Therapeutics' IND application for NUZ-001, which removes the regulatory hold after nine months and allows the biotech to join the Healy ALS (motor neurone disease) platform trial.

Morgans sees this as a major de-risking for the stock. First patient enrolments in the Healy trial are expected by the end of 2025, with first data at the end of 2026.

The analyst continues to believe Neurizon is a robust proposition in the rare disease segment.

Speculative Buy rating retained. Target slips to 39c from 42c.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.

06/10/2025

1

Buy

$0.52

235.48%

Removing a key overhang on the Neurizon Therapeutics share price, suggests Petra Capital, the US FDA has lifted the clinical hold on its investigational new drug (IND) application for NUZ-001.

This outcome clears the path to join the potentially registrational Healy ALS platform trial in 4QCY25, explains the broker.

Petra Capital views this as a major milestone and de-risking event, validating the robustness of pre-clinical, clinical, and manufacturing data for NUZ-001 and its active ingredient, monepantel.

IND acceptance enhances the company's credibility with potential partners and supports future expansion into other neurodegenerative conditions, points out the analyst. Dosing in the HEALEY ALS trial is expected to begin by December 2025.

Petra Capital raises its target price to 56c from 52c and retains a Buy rating.

FORECAST
Petra Capital forecasts a full year FY26 EPS of minus -3.40 cents.
Petra Capital forecasts a full year FY27 EPS of minus -3.00 cents.